Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein

Laura A. Laviolette(Harvard University), Julien Mermoud(Harvard University), Isabel A. Calvo(Harvard University), N. Eric Olson(Harvard University), Myriam Boukhali(Harvard University), Ortrud K. Steinlein(Institute of Human Genetics), Elisabeth Roider(Ludwig-Maximilians-Universität München), Elke Sattler(Ludwig-Maximilians-Universität München), Dachuan Huang(Duke-NUS Medical School), Bin Tean Teh(Duke-NUS Medical School), Mo Motamedi(Harvard University), Wilhelm Haas(Harvard University), Othon Iliopoulos(Massachusetts General Hospital)
Nature Communications
June 28, 2017
Cited by 49Open Access
Full Text

Abstract

Abstract Germline mutations in the Folliculin ( FLCN ) tumour suppressor gene result in fibrofolliculomas, lung cysts and renal cancers, but the precise mechanisms of tumour suppression by FLCN remain elusive. Here we identify Rab7A, a small GTPase important for endocytic trafficking, as a novel FLCN interacting protein and demonstrate that FLCN acts as a Rab7A GTPase-activating protein. FLCN −/− cells display slower trafficking of epidermal growth factor receptors (EGFR) from early to late endosomes and enhanced activation of EGFR signalling upon ligand stimulation. Reintroduction of wild-type FLCN, but not tumour-associated FLCN mutants, suppresses EGFR signalling in a Rab7A-dependent manner. EGFR signalling is elevated in FLCN −/− tumours and the EGFR inhibitor afatinib suppresses the growth of human FLCN −/− cells as tumour xenografts. The functional interaction between FLCN and Rab7A appears conserved across species. Our work highlights a mechanism explaining, at least in part, the tumour suppressor function of FLCN.


Related Papers

No related papers found

Powered by citation graph analysis